Korro Bio Inc.

Korro Bio is a privately held biotechnology company focused on the discovery and development of a new class of precision genetic medicines utilizing our propriety RNA editing platform, OPERA. Our portfolio of innovative RNA therapies has the potential to propel genetic medicine beyond rare genetic diseases into larger patient populations with common diseases. Korro enjoys support from a committed group of institutional investors, and recently completed a $116 million Series B financing round to advance our current and future work. We are located in Cambridge, Massachusetts.

We are collaborative and united by a common mission.  We are building a company with extraordinary people with an audacious vision to create transformative genetic medicines for prevalent diseases.  Our values – Rewrite the future, On the Cutting Edge, Better Together, Dynamically Different, Kindness and Integrity form the fabric of the organization.  They are reinforced daily and serve as key dimensions in the hiring process to help us ensure that Korro is a magnet for outstanding talent and a great place to work.